Flagship Harbor Advisors’s Iterum Therapeutics ITRM Stock Holding History

Flagship Harbor Advisors’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,000	Closed	-$600	–	769
2026 Q1	$600	Buy	+20,000	New	+$5.01K	﹤0.01%	731

Other funds holding ITRM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

CCMW

Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return

Flagship Harbor Advisors's ITRM Position: Q2 2026 in Review

Flagship Harbor Advisors sold out of Iterum Therapeutics (ITRM) in Q2 2026, closing a stake of 20,000 shares — an estimated $600 sold.

Flagship Harbor Advisors first reported a position in ITRM in Q1 2026 and held it in 1 quarter. The position peaked at $600 in Q1 2026. 2 funds tracked by Wall St. Rank hold ITRM as of Q2 2026.

Flagship Harbor Advisors reported no remaining Iterum Therapeutics position as of Q2 2026 after selling out during the quarter.
Flagship Harbor Advisors sold 20,000 Iterum Therapeutics shares in Q2 2026, an estimated $600.
Flagship Harbor Advisors first reported a position in Iterum Therapeutics in Q1 2026 and held it in 1 quarter.
Flagship Harbor Advisors's Iterum Therapeutics position peaked at $600 in Q1 2026.
2 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2026.

Based on Flagship Harbor Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.